Channels - Cerebrovascular reactivity and plasma p‐tau181 in Alzheimer's disease: Insights into APOE‐related vascular phenotypes :: FRELIP Discovery

Similar Items: Cerebrovascular reactivity and plasma p‐tau181 in Alzheimer's disease: Insights into APOE‐related vascular phenotypes

Quick Look
Impact of plasma pTau181 levels on clinician diagnostic confidence and management in memory and cognition clinics: A multi‐site before‐and‐after study
Quick Look
Metabolic and renal factors associated with plasma phosphorylated tau analytes used to detect Alzheimer's disease pathology
Quick Look
Aβ‐ and tau‐associated neuroinflammatory signatures in Alzheimer's disease
Quick Look
APOE‐associated disease risk and sex‐specific effects in Egyptian Alzheimer's disease: an exploratory study
Quick Look
Transient plasma p‐tau217 elevations after electroconvulsive therapy: A two‐case report
Quick Look
Associations of plasma p‐Tau217 with cognitive domain performance in clinically unimpaired participants: Evidence from HABS‐HD
Quick Look
Reframing Alzheimer's disease as a complex adaptive system: More than an amyloid beta–tau connection
Quick Look
Investigating the amyloid–tau–neurodegeneration framework in Alzheimer's disease using semi‐supervised multimodal imaging data fusion
Quick Look
Blood DNA methylation signature of cognitive reserve moderates the association between CSF tau pathology and memory in prodromal Alzheimer's disease
Quick Look
Heritability of Alzheimer's disease–related plasma biomarkers in the Amish population
Quick Look
Cerebrospinal fluid NPTX2/p‐tau ratio as a biomarker for cognitive decline in neurodegenerative diseases
Quick Look
Evaluation of fully automated ApoE4 proteotyping for APOE ε4 genotype estimation in the FINDERI cohort
Quick Look
Exploring the spatial covariance of cerebral vascular density and amyloid burden in Alzheimer's disease
Quick Look
A fovea‐centered retinal signature linked to plasma biomarkers in prodromal Alzheimer's disease
Quick Look
The effect of treating hearing loss with hearing aids on plasma biomarkers of Alzheimer's disease and related dementias
Quick Look
Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
Quick Look
Single‐subject proteomic signatures in Alzheimer's disease reflect clinical phenotypes and distinguish asymptomatic from symptomatic cases
Quick Look
A diagnostic plasma omics‐biomarker for Alzheimer's disease informed by microglial single‐cell transcriptomics: A pilot study
Quick Look
APOE ε4, modifiable risk factors, and dementia in community‐based older Japanese adults
Quick Look
Alzheimer's disease drug development pipeline: 2026
Quick Look
Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging
Quick Look
Atrophy signature for alpha‐synuclein copathology in Alzheimer's disease
Quick Look
Interchangeability of CSF and PET to identify Alzheimer's disease pathology
Quick Look
Novel insights into early Alzheimer's disease: quantitative gradient recalled echo MRI reveals preatrophic neuronal and myelin injury concurrent with emerging amyloid pathology